Clinical Observation of Erlotinib Combined with Bevacizumab in First-line Treatment of EGFR Sensitive Mutation Positive Advanced Non-small Cell Lung Cancer
Objective To observe the clinical efficacy of erlotinib combined with bevacizumab in first-line treatment of advanced non-small cell lung cancer with positive epidermal growth factor receptor(EGFR)sensitive mutations.Methods A prospective randomized controlled study was conducted,selected advanced non-small cell lung cancer patients with positive EGFR sensitive mutations as the study subjects.The patients were divided into the control group and the observation group using a ran-dom number table method.The control group received treatment with erlotinib,while the observation group received treatment with erlotinib combined with bevacizumab.The clinical efficacy,serum tumor marker levels[carcinoembryonic antigen(CEA),cytoker-atin 21-1 fragment(CYFRA21-1),vascular endothelial growth factor(VEGF)],immune function[leukocyte differentiation anti-gen 3(CD3),leukocyte differentiation antigen 4(CD4),leukocyte differentiation antigen 8(CD8)],and adverse drug reactions were compared between 2 groups of patients.Results After 3 months of treatment,the objective response rate(ORR)and disease control rate(DCR)of the observation group were higher than those of the control group,with a statistical significant difference(P＜0.05).After treatment,the serum CEA,CYFRA21-1,and VEGF levels in the observation group were lower than those in the control group,with a statistical significant difference(P＜0.05).The CD3+,CD4+,CD4+/CD8+levels in the observation group were higher than those in the control group,while CD8+levels were lower than those in the control group,with a statistical signifi-cant difference(P＜0.05).There was no statistical significant difference in the incidence of adverse reactions between the 2 groups of patients(P＞0.05).Conclusion The combination of erlotinib and bevacizumab first-line treatment can effectively im-prove the clinical efficacy and immune function of EGFR sensitive mutation positive advanced non-small cell lung cancer patients.
万方数据
维普
